SCHEMBL5049958

SCHEMBL5049958

CC(C)(C)OC(=O)NC1(C(=O)N(C(N)=O)c2cccs2)CCC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.35
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
CTSK P43235 2/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CTSS P25774 1/20 0.32
HSD11B1 P28845 2/20 0.32
ALDH1A1 P00352 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
METAP1 P53582 1/20 0.31
FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10627220 0.74 ALOX5 (0.38) CTSKMAPTSMN1; SMN2CTSSALDH1A1
SCHEMBL5049956 0.72 GHSR (0.37) GHSRHSD11B1FAAH
SCHEMBL8174534 0.71 TSHR (0.46) MAPTSMN1; SMN2ALDH1A1
SCHEMBL5049960 0.70 GAA (0.43) MAPTSMN1; SMN2ALDH1A1
SCHEMBL4742076 0.70 KMT2A (0.36) GHSRHSD11B1
SCHEMBL4739921 0.69 GPR119 (0.35) HDAC3HDAC1HDAC2MAPTALDH1A1
SCHEMBL6644052 0.67 HDAC3 (0.42) HDAC3HDAC1HDAC2CTSKMAPT
SCHEMBL2716648 0.67 KMT2A (0.36) GHSRPSEN1PSEN2APH1BNCSTN
SCHEMBL2051406 0.67 GHSR (0.33) GHSR
SCHEMBL2482164 0.66 P2RX7 (0.35) GHSRMAPTALDH1A1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207528-A1 Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207528-A1 Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline GLS2, SLC10A1, UGT1A1 GHSR 3301/4885HDAC3 1803/4885HDAC1 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.